摘要
目的比较单纯放射治疗及放疗联合替莫唑胺治疗高级别胶质瘤的有效性以及不良反应。方法 86例术后病理证实间变性星形细胞瘤及胶质母细胞瘤随机分为单纯放疗(RT)以及放疗联合替莫唑胺治疗组,研究两组患者治疗有效率、生活质量和药物安全性。结果两组间各项临床病理特征相似,其中病灶未完全切除患者共62例。术后放疗联合替莫唑胺组(RT-TMZ)以及单纯放射治疗(RT)组的近期总有效率分别为87.5%和60.0%(P<0.05)。RT-TMZ组中位生存期为16.2月,RT组仅10.7月(P<0.05)。RT-TMZ组的1、2年生存率分别为74.4%和46.5%,明显高于单纯RT组(P<0.05)。而RT-TMZ组患者对治疗的耐受性良好,常见不良反应是骨髓抑制和呕吐。结论术后放疗联合替莫唑胺化疗治疗高级别胶质瘤能有效提高治疗有效率及生活质量,提高患者无瘤生存期,且患者耐受性较好。
Objective To evaluate the efficacy and safety of postoperative radiotherapy combined with temozolomide in the treatment of high-grade gliomas.Methods Eighty-six patients with postoperative malignant gliomas confirmed by histopathology were randomly divided into 2 groups：43 patients were treated by radiotherapy combined with temozolomide（RT-TMZ group） and 43 patients received radiotherapy alone（RT group）.The overall response rate,toxicity and the quality of life（QOL） were observed.Results The overall response rate was 87.5% in RT-TMZ group and 60.0% in RT group（P0.05）.The median survival time was 16.2 months in RT-TMZ group,which was higher than that of RT group（10.7 months,P0.05）.In addition,the 1-and 2-year survival rates in RT-TMZ group were 74.4% and 46.5%,which were higher than those in RT group（P0.05）.All patients well tolerated the treatment scheme.The major toxicities in RT-TMZ group were myelosuppression and vomiting.Conclusion Radiotherapy combined with temozolomide tends to show a more favorable treatment efficacy,longer survival time and better QOL than radiotherapy alone and is well tolerated for patients of postoperative high-grade gliomas.
出处
《实用肿瘤杂志》
CAS
北大核心
2010年第6期653-656,共4页
Journal of Practical Oncology
